Back to Search
Start Over
Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma.
- Source :
-
Hematology . 2019, Vol. 24 Issue 1, p440-445. 6p. 1 Chart. - Publication Year :
- 2019
-
Abstract
- Anaplastic lymphoma kinase negative anaplastic large cell lymphoma (ALK- ALCL) is a definite entity in the WHO 2016 Classification that represents 2–3% of non-Hodgkin lymphoma (NHL) and 12% of T-cell NHL cases. ALK- ALCL lacks ALK protein expression, but expresses CD30 and has morphologic features similar to ALK positive anaplastic large cell lymphoma (ALK+ ALCL). Some studies indicate that ALK- ALCL and ALK+ ALCL possess different molecular and genetic characteristics. Besides, ALK- ALCL is worse than ALK+ ALCL in terms of treatment outcome, prognosis, and long-term survival. This review is aimed at summarizing information about ALK- ALCL, especially with respect to the treatment and prognosis. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 10245332
- Volume :
- 24
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Hematology
- Publication Type :
- Academic Journal
- Accession number :
- 136406063
- Full Text :
- https://doi.org/10.1080/16078454.2019.1613290